The goal of this application is to develop and characterize novel vaccine carriers to HIV-1 antigens based on El-deleted adenoviral recombinants derived from chimpanzee serotypes in pre-clinical animal models. Such serotypes of adenovirus do not circulate in the human population. They should induce responses to the HIV-1 antigens that are unimpaired by pre-existing neutralizing antibodies to the vaccine carrier. Such antibodies are expected to reduce the efficacy of vaccines based on common human serotypes of adenovirus in a human target population. Projects 1 and 2 will generate additional vaccine carriers for booster immunizations. Project I will generate recombinants derived from alternate chimpanzee serotypes (C5, C6 or C7). This Project will also construct a molecular clone for the chimpanzee serotype 68 of adenovirus (AdC68) and other viruses that will be developed further as vaccines to facilitate the generation of recombinants free of potential contaminants. Project 2 will focus on the hexon of AdC68 virus, and generate artificial serotypes by site-directed mutagenesis using structural information from X-ray crystallography and modeling as well as epitope mapping of virus neutralizing antibodies. Project 3 will test the already developed vaccines based on AdC68 virus, as well as the novel constructs developed by Projects 1 and 2, for induction of immune responses to gag/pol/nef and gp140 of HIV-1 clades B and C in rodents. Project 4 will test SIVmac239 gag/pol/nef or HIV-1 gp140 clade C constructs for induction of T and B cell responses and protection to SHIV89.6P, SIVmac231 or a newly-developed clade C SHIV challenge in non-human primates. Two Cores will support the Program. Core 1 is an Administrative Core, while Core 2 is a Vector Core that will provide the investigators of Projects 1-4 with adenoviral recombinants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI052271-02
Application #
6658925
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (55))
Program Officer
Pensiero, Michael N
Project Start
2002-09-15
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
2
Fiscal Year
2003
Total Cost
$1,836,451
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Emmer, Kristel L; Wieczorek, Lindsay; Tuyishime, Steven et al. (2016) Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. AIDS 30:2405-2414
Lasaro, Marcio O; Sazanovich, Marina; Giles-Davis, Wynetta et al. (2011) Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther 19:1727-36
Small, Juliana C; Ertl, Hildegund C J (2011) Viruses - from pathogens to vaccine carriers. Curr Opin Virol 1:241-5
Zhou, Dongming; Zhou, Xiangyang; Bian, Ang et al. (2010) An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5:1775-1785
Lasaro, Marcio O; Ertl, Hildegund C J (2010) Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 22:385-90
Pichla-Gollon, Susan L; Lin, Shih-Wen; Hensley, Scott E et al. (2009) Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 83:5567-73
Tatsis, Nia; Lasaro, Marcio O; Lin, Shih-Wen et al. (2009) Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182:6587-99
Santra, Sampa; Sun, Yue; Korioth-Schmitz, Birgit et al. (2009) Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-45
Haut, Larissa Herkenhoff; Ertl, Hildegund C J (2009) Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J Leukoc Biol 86:779-93
Lasaro, Marcio O; Tatsis, Nia; Hensley, Scott E et al. (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14:205-12

Showing the most recent 10 out of 22 publications